Ec healthcare (02138.HK) announced that as of March 31, 2024, the group's revenue and sales were HKD 42.11 million and HKD 42.1 million, respectively, an increase of 8.7% and 8.5% year-on-year. The group's internal growth increased by 5.8% year-on-year to HKD 41 million, driven by the growth of the medical division, which introduced additional service points since the last fiscal year, and the gradual recovery of mainland visitors to Hong Kong, leading to growth in aesthetic medical and beauty services.

The group's after-tax net profit during the reporting period fell 85.3% year-on-year to HKD 15.7 million, while the equity shareholder's share of the loss was HKD 18.9 million. This is mainly due to (i) the temporary low operating leverage of new service points established by the company since the last fiscal year; (ii) cost increases caused by inflation; (iii) the increase in depreciation and amortization expenses generated by the company's internal expansion in the previous year; (iv) the increase in interest expenses caused by the rise in interest rates of about HKD 44 million; and (v) the reduction of subsidies of about HKD 43.4 million under the Hong Kong government's employment protection scheme.